福元医药：盐酸阿罗洛尔片获得药品注册证书

Core Viewpoint - The company has received the drug registration certificate for Arolol hydrochloride tablets (10mg) from the National Medical Products Administration, allowing for production approval [1] Group 1: Drug Approval - The drug Arolol hydrochloride is indicated for primary hypertension, angina pectoris, tachyarrhythmias, and essential tremor [1] - The company received the acceptance notice for the application on March 26, 2024, and has recently obtained the approval from the National Medical Products Administration [1] - The approval of the drug registration certificate is considered equivalent to passing the consistency evaluation according to national policies [1] Group 2: R&D Investment - The total R&D investment for the drug Arolol hydrochloride has reached RMB 3.9707 million (unaudited) as of the date of the announcement [1]